AXLA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 15:59):

Stats
Today's Volume	6 782.00
Average Volume	54 521.00
Market Cap	1.18M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0220
ATR14	$0.625 (155.90%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-01	Koziel Margaret	Sell	679	Common Stock
2023-02-17	Koziel Margaret	Buy	70 000	Stock Option (Right to Buy)
2023-02-17	Hinshaw William	Buy	275 000	Stock Option (Right to Buy)
2023-02-17	Fehlner Paul	Buy	70 000	Stock Option (Right to Buy)
2023-02-10	Fehlner Paul	Buy	5 221	Common Stock

INSIDER POWER
99.85
Last 92 transactions
Buy: 44 458 855 \| Sell: 477 523

Volume Correlation

Long: 0.47 (neutral)

Short: 0.41 (neutral)

Signal:(20.847) Neutral

Axcella Health Inc Correlation

10 Most Positive Correlations
SEED	0.947
DZSI	0.941
POTX	0.94
INO	0.937
VIVE	0.933
RKDA	0.927
CHB	0.926
KRKR	0.926
PRPO	0.925
AQB	0.925

10 Most Negative Correlations
MPRA	-0.943
NCAC	-0.941
APXI	-0.936
VMGA	-0.93
SCRM	-0.927
ALSA	-0.927
ZING	-0.926
TRON	-0.926
ARTEU	-0.924
ADAL	-0.921

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Axcella Health Inc Correlation - Currency/Commodity

-0.60
( weak negative )

-0.21
( neutral )

0.12
( neutral )

0.19
( neutral )

0.23
( neutral )

0.09
( neutral )

Axcella Health Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.520

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0463

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0512

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Axcella Health Inc

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.